Kbc Group Nv Arcus Biosciences, Inc. Transaction History

Kbc Group Nv

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$13.43 - $19.63 $27,880 - $40,751	-2,076 Reduced 51.54%	1,952 $37,000
Q3 2023 Feb 15, 2024	SELL	$17.62 - $23.54 $36,579 - $48,869	-2,076 Reduced 51.54%	1,952 $35,000
Q3 2022 Feb 15, 2024	BUY	$23.23 - $30.07 $48,225 - $62,425	2,076 Added 106.35%	4,028 $105,000
Q2 2022 Feb 14, 2024	BUY	$17.23 - $37.73 $35,769 - $78,327	2,076 Added 106.35%	4,028 $102,000
Q2 2022 Jul 26, 2022	BUY	$17.23 - $37.73 $69,402 - $151,976	4,028 New	4,028 $102,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.